Table 1.

Baseline characteristics of studied population

VariableCategoriesBaricitinib
(TC = 240; 240 patients)
Mean (SD)
Otherwise: n %
TNFi
(TC = 461; 397 patients)
Mean (SD)
Otherwise: n %
OMA bDMARDs
(TC = 278; 253 patients)
Mean (SD)
Otherwise: n %
P values
Concomitant csDMARD at baseline45 %54 %46 %0.02
Line of Therapy1st20 %46 %22 %<0.01
2nd22 %25 %26 %
3rd14 %14 %26 %
4th or later43 %16 %27 %
Gender (female)80 %71 %74 %0.05
Age59 (13)53 (14)59 (13)<0.01
Seropositivity (ACPA and/or RF)75 %71 %79 %0.04
HAQ-DI Score0.9 (0.7)0.7 (0.6)0.8 (0.6)0.02
Disease duration (years)12 (10)9 (10)11 (9)<0.01
CDAI baseline19 (10)15 (12)19 (14)0.09
  • Legend

  • TC = Treatment Courses. SD = Standard Deviation. TNFi = TNF inhibitors. OMA bDMARDs = Other Mode of Action biological DMARDs. csDMARD = conventional synthetic DMARD. ACPA = Anti Citrullinated Peptide Antibodies. RF = Rheumatoid Factor. HAQ-DI= Health Assessment Questionnaire Disability Index. CDAI = Clinical Disease Activity Index.